New Fully Integrated Developability and Optimization Service
Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line DevelopmentRead More
Abzena and Lipum AB sign integrated CMC agreement to produce a novel biologic for autoimmune inflammatory diseases
Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory diseases, including juvenile idiopathic arthritis.Read More
Technologies and Solutions
Abzena provides proprietary technologies and complementary solutions to organisations involved in the development of biopharmaceutical products.
Latest News and Events
Abzena presents its latest research and exhibits at events all over the world.
Find out where we are next and our latest news below.
Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects
BioProcess International East
9 September 2019
Abzena expands leadership team with Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer
10 September 2019
Resources and Downloads
Find our latest videos, brochures and fact sheets in our resources section.
Download our Brochure
Technology & Solutions BrochureDownload File
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs)…Read More
Cell Line Development Lab Tour
Abzena has over 10 years experience in Cell Line Development for customers and has completed…